Chad Ritch, MD, discusses differences between PSMA-PET imaging agents and the need for further evidence to guide clinical decision-making.
|Articles|November 1, 2003
Not all bond mutual funds are created equal
Author(s)Joel M. Blau, CFP
Q My broker is suggesting that I invest in bonds, specifically bondmutual funds. After reviewing the literature, I'm confused by the differencesamong the mutual fund choices. What are the real differences?
Advertisement
Advertisement
Related to this article
The final analysis confirmed PFS and response benefits in previously treated advanced clear cell renal cell carcinoma, but the OS difference did not cross the prespecified significance boundary.
Chad Ritch, MD, discusses how PSMA-PET informs patient management across different stages of the prostate cancer journey.
Topline results are expected in November 2026 ahead of a planned sBLA submission.
Alicia K. Morgans, MD, MPH, reviews promising prostate cancer findings from ESMO 2026,
A comprehensive guide to the top data in genitourinary oncology presented at ESMO 2026.
Brian I. Rini, MD, FASCO, explains why LITESPARK-012’s negative triplet results still offer lessons on drug delivery and building on first-line RCC doublets.
Topline results from the study are anticipated in the first half of 2027.
Advertisement
Advertisement
Trending on Urology Times
1
Nogapendekin alfa inbakicept plus BCG advances to final analysis in BCG-naïve NMIBC
2
Factors shaping PSMA-PET agent selection in prostate cancer
3
Comparing PSMA-PET agents: What urologists should know
4
Alicia Morgans, MD, MPH, highlights key prostate cancer data from ESMO 2026
5